| Popis: |
Qingqing Chen,1,2 Dandan Yin,1,3 Pei Li,1,3 Yan Guo,1,3 Desong Ming,2 Yuling Lin,2 Xiaoli Yan,2 Zhishan Zhang,2 Fupin Hu1,3 1Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China; 2The Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou, People’s Republic of China; 3Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, People’s Republic of ChinaCorrespondence: Zhishan ZhangDepartments of Clinical Laboratory, The Affiliated Quanzhou First Hospital of Fujian Medical University, No. 248 East Street, Quanzhou City, Fujian Province 362002, People’s Republic of ChinaTel +86-595-22277352Fax +86-595-22278131Email 15859775058@139.comFupin HuInstitute of Antibiotics, Huashan Hospital, Fudan University, 12 M. Wulumuqi Road, Shanghai 200040, People’s Republic of ChinaTel +86-21-52888186Fax +86-21-62488290Email hufupin@fudan.edu.cnAbstract: A linezolid-resistant E.faecalis strain harboring optrA and cfr resistance genes were isolated from a patient in china, which had no mutations in rplC, rplD, rplV, and 23S rRNA gene. Transformation indicated that optrA and cfr were located on two different plasmids and both could be transferred to recipient strain, resulting in the increase of MICs of linezolid and chloramphenicol. Cfr, carried by an 11,872-bp plasmid, was enclosed with an IS 110 transposase in upstream and an IS 3-like transposase in downstream, while optrA was on an 8357-bp plasmid. As far as we know, this is the first report of an E.faecalis clinical strain co-harboring optrA and cfr in China.Keywords: E.faecalis, linezolid, cfr, optrA |
